Obicetrapib
Post hoc BROADWAY/BROOKLYN analysis: obicetrapib attenuates kidney function decline, tracking with achieved HDL-C (Am J Prev Cardiol 2026)
Original title: Cholesteryl ester transfer protein inhibition with obicetrapib is associated with attenuated decline in kidney function in patients at high cardiovascular risk: Post hoc pooled results from the BROADWAY and BROOKLYN trials
A post hoc pooled analysis of the BROADWAY (n = 2,530) and BROOKLYN (n = 354) trials, in which patients with heterozygous familial hypercholesterolaemia or established atherosclerotic cardiovascular disease on maximally tolerated lipid-lowering therapy took obicetrapib 10 mg daily or placebo for 365 days. Among 2,832 participants with a post-baseline renal assessment, obicetrapib attenuated eGFR decline versus placebo (mean difference 0.67 mL/min/1.73 m2, nominal P = 0.02; on-treatment 0.82, P = 0.0139), with nominally fewer eGFR declines of 40% or more (1.3% versus 1.9%) and renal composite events (1.9% versus 3.0%, hazard ratio 0.64, nominal P = 0.08). Higher achieved HDL-C independently tracked with lower renal risk. Nominal significance only, hypothesis-generating for a mechanism, not a pre-specified renal endpoint.
Original abstract
Background: Patients with cardiovascular disease have increased risk of chronic kidney disease progression. Low levels of high-density lipoprotein (HDL) or HDL dysfunction have been implicated in progressive deterioration of renal function. We investigated the impact on renal function of obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor that raises apolipoprotein A1 and HDL cholesterol (HDL-C) and improves HDL function.
Methods: BROADWAY (N = 2530) and BROOKLYN (N = 354) were double-blind, placebo-controlled trials of patients with heterozygous familial hypercholesterolemia and/or established atherosclerotic cardiovascular disease taking maximally tolerated lipid-lowering therapy assigned to 365-day treatment with the novel CETP inhibitor, obicetrapib 10 mg/d, or placebo. In a post hoc pooled trial analysis of randomized participants with at least 1 post-baseline renal assessment (estimated glomerular filtration rate [eGFR] n = 2832; urine albumin-to-creatinine ratio [UACR] n = 1897), renal function and its association with HDL-C were evaluated.
Results: Participants in BROADWAY and BROOKLYN had mean (±SD) baseline eGFR 84.4 ± 17.9 and 91.8 ± 17.8 mL/min/1.73 m² and median albumin-to-creatinine ratio 11.0 and 8.0 mg/g, respectively. Obicetrapib attenuated kidney function decline vs placebo (mean difference = 0.67 mL/min/1.73 m², nominal P = 0.02); on-treatment analysis strengthened this signal (0.82; nominal P = 0.0139). Obicetrapib-treated patients had nominally fewer cases of eGFR <15 mL/min/1.73 m2 (0 vs 0.2 %),≥40 % eGFR declines (1.3 vs 1.9 %), and a renal events composite (1.9 vs 3.0 %; hazard ratio 0.64, nominal P = 0.08). Higher achieved HDL-C was associated with lower renal composite event risk (spline nominal P < 0.0001), independent of baseline HDL-C and eGFR. Annualized percent change in UACR was not significantly different between groups.
Conclusion: In patients at high cardiovascular risk, CETP inhibition with obicetrapib may attenuate kidney function decline, potentially through its HDL-raising effects.
HDL biologykidneyobicetrapibsafety
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.